VolitionRX (NYSEAMERICAN:VNRX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday. They currently have a $10.00 target price on the medical research company’s stock. HC Wainwright’s price objective indicates a potential upside of 171.74% from the stock’s previous close.
VolitionRX (VNRX) traded up $0.06 during trading hours on Monday, hitting $3.68. The stock had a trading volume of 150,729 shares, compared to its average volume of 146,185. VolitionRX has a 1-year low of $2.08 and a 1-year high of $4.77. The company has a market cap of $93.67, a price-to-earnings ratio of -7.23 and a beta of -1.46.
VolitionRX (NYSEAMERICAN:VNRX) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01).
WARNING: “VolitionRX (VNRX) Rating Reiterated by HC Wainwright” was posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/29/volitionrx-vnrx-rating-reiterated-by-hc-wainwright.html.
VolitionRX Company Profile
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.